Health Care·Pharmaceuticals·$277.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.45 | N/A | +19.34% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.45 | N/A | +19.34% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Overall, management expressed satisfaction with the EPS results. However, they did not provide specific guidance for future quarters.
Management highlighted strong performance in key therapeutic areas.
They emphasized ongoing commitment to innovation and pipeline development.
This earnings report shows that Novartis performed well on earnings per share, exceeding expectations significantly. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors will need to monitor upcoming developments and the company's pipeline closely.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Apr 19, 2010